Study on How Immune-inflammatory Biomarkers and Oxytocin Affect Psychotherapy Response in Adults With Posttraumatic Stress Disorder

What this Trial Is About

Researchers are investigating how immune-inflammatory biomarkers interact with the oxytocin system to influence the development of posttraumatic stress disorder PTSD and its response to psychotherapy. This observational study includes adults with PTSD symptoms and aims to understand biological factors that may affect treatment resistance and recovery. The study is sponsored by Shalvata Mental Health Center and focuses on trauma-related distress and psychotherapy outcomes. Participants will undergo weekly psychotherapy sessions for 12 weeks, with scheduled assessments of oxytocin and inflammatory markers such as IL-1b2, IL-6, and TNF-b1 in saliva before and after sessions 1, 6, and 12. Self-report questionnaires measuring PTSD symptoms, depression severity, and general anxiety will be completed after these sessions. The study also evaluates psychological resilience and the working alliance between patient and therapist. Throughout the study, participants will provide saliva samples and complete surveys to monitor changes in biological markers and mental health symptoms. Researchers will measure the relationship between these biomarkers and treatment progress over the 12 to 16 week period depending on treatment duration. The study aims to provide insights into factors influencing psychotherapy responsiveness, with ongoing safety and symptom monitoring.

The Predictive Role of Immune-inflammatory Biomarkers and Their Interaction With the Oxytocin System in Trauma-related Psychotherapy Responsiveness